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Background: Hypercholesterolemia arising from abnormal lipid metabolism is one of the critical risk factors for
coronary artery disease (CAD), however the roles of genetic variants in lipid metabolism-related genes on premature
CAD (≤60 years old) development still require further investigation. We herein genotyped four single nucleotide
polymorphisms (SNPs) in lipid metabolism-related genes (rs1132899 and rs5167 in APOC4, rs1801693 and rs7765781
in LPA), aimed to shed light on the influence of these SNPs on individual susceptibility to early-onset CAD.
Methods: Genotyping of the four SNPs (rs1132899, rs5167, rs1801693 and rs7765781) was performed in 224
premature CAD cases and 297 control subjects (≤60 years old) using polymerase chain reaction-ligation detection
reaction (PCR–LDR) method. The association of these SNPs with premature CAD was performed with SPSS software.
Results: Multivariate logistic regression analysis showed that C allele (OR = 1.50, P = 0.027) and CC genotype
(OR = 2.84, P = 0.022) of APOC4 rs1132899 were associated with increased premature CAD risk, while the other three
SNPs had no significant effect. Further stratified analysis uncovered a more evident association with the risk of
premature CAD among male subjects (C allele, OR = 1.65, and CC genotype, OR = 3.33).
Conclusions: Our data provides the first evidence that APOC4 rs1132899 polymorphism was associated with an
increased risk of premature CAD in Chinese subjects, and the association was more significant among male subjects.
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Coronary artery disease (CAD) is the predominant
cause of death and morbidity worldwide. Previous stud-
ies and clinical trials have established numerous envir-
onmental factors contributing to the development of
CAD [1], such as obesity, hypercholesterolemia, alcohol
intake, smoking, diabetes and hypertension [2]. Among
the above risk factors, hypercholesterolemia arising
from abnormal lipid metabolism has been considered to
be one of the most key risk factors for CAD pathogenesis
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tions of genetic variants or polymorphisms in candidate
genes with the risk of CAD, especially the early-onset
CAD [5–7].
Age is a critical contributing factor for the risk of
CAD, age-related functional impairment including weak
immune and inflammatory system, and other mecha-
nisms involved in the regulation of the flow in the cor-
onary arteries, exerted crucial effects during CAD
development [8]. Thus, in order to exclude the effects of
age-related dysfunction of CAD associated mechanisms,
the association analysis of these four SNPs in lipids
metabolism-related genes with the risk of CAD was per-
formed only among the early-onset CAD subjects.
Nonetheless, the definition for early-onset CAD patients
discriminating from late-onset CAD is unspecific. In thisdistributed under the terms of the Creative Commons Attribution License
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younger than 60 years old, according to several previous
published studies [9, 10].
Apolipoprotein C-IV (APOC4), a highly conserved
lipid-binding protein belonging to the apolipoprotein C
family, exerts a critical role in lipid metabolism [11, 12].
The APOC4 gene is located on the chromosome 19q12-
13.2, constructs the APOE/C1/C4/C2 gene cluster with
apolipoprotein CI (APOC1), apolipoprotein CII (APOC2)
and apolipoprotein E (APOE) [13], which is closely asso-
ciated with plasma lipid levels, atherosclerotic plaque
formation, and thus with the development of coronary
artery disease and alzheimer’s disease [14, 15]. APOC4 is
predominantly associated with very low-density lipopro-
tein (VLDL), and plays an important role in triglyceride
metabolism [15]. Overexpression of apolipoprotein C-IV
in transgenic mice can cause hypertriglyceridemia [16].
Moreover, previous study has revealed a significant asso-
ciation of rs5167 (Leu96Arg) and rs1132899 (Leu36Pro)
polymorphisms in APOC4 gene with triglyceride levels
in women [17]. In addition, the T allele of APOC4
rs5167 polymorphism conferred modest effects on high
density lipoprotein cholesterol (HDL-C) and apoAI
levels [15]. Thus it was reasonable to speculate that
APOC4 polymorphisms might probably play an import-
ant role in CAD pathogenesis through impacting on
plasma lipid profile.
Lipoprotein (LPA), also refers to as lipoprotein (a), a
large glycoprotein attached to the low-density lipopro-
tein (LDL)-like particles, has been demonstrated to be
associated with the risk of coronary artery disease [18].
LPA is highly homologous with plasminogen, can bind
to the lysine sites available for plasminogen on the sur-
face of fibrin, and thereby compete with plasminogen to
interfere with the fibrinolytic process and inhibit its acti-
vation, which increases the formation of thrombosis, and
finally promotes the atherogenesis and coronary artery
disease pathogenesis [19, 20]. Additionally, the elevated
LPA levels and corresponding genotypes were associated
with increased risk of aortic valve stenosis (AVS) [21].
Genome-wide association study (GWAS) has revealed
that the SLC22A3-LPAL2-LPA gene cluster was a risk
locus for coronary artery disease, and the chromosomal
region (6p26) where the SLC22A3-LPAL2-LPA gene clus-
ter located is closely associated with the risk of CAD, and
the LPA locus on 6q26-27 encoding lipoprotein has the
strongest association [22]. Recent studies illustrated that
the G allele of rs10455872, and the C allele of rs3798220
in LPA gene significantly elevated the LPA levels in periph-
eral blood, and the two SNPs in LPA were demonstrated
to be the critical risk factors for CAD development, indi-
cating that LPA polymorphisms were associated with CAD
risk [23]. We herein focused on two other LPA polymor-
phisms (rs1801693 and rs7765781) in its exons, in order toinvestigate into the associations of these two SNPs with
premature CAD risk.
Single nucleotide polymorphisms (SNPs) have been
established to influence individual susceptibility for di-
verse human diseases. Accumulating evidences have sug-
gested that SNPs within the lipid metabolism-related
genes might potentially contribute to CAD [24–27].
Nonetheless, the genetic causes and underlying molecu-
lar mechanisms of these candidate genes for CAD re-
quire to be elucidated. Since aging effects, including
weak immune system and relative high level exposure to
environmental risk factors, rather than direct genetic ef-
fects, contribute to the risk of CAD in older subjects.
Thus, we herein conducted a case–control study to in-
vestigate the association of the four SNPs in the lipid
metabolism-related genes (rs5167 and rs1132899 in
APOC4, rs1801693 and rs7765781 in LPA) with the risk
of premature CAD (≤60 years old). Our data revealed
that the C allele of rs1132899 in APOC4 has a significant




Two hundred twenty-four CAD patients and 294 control
subjects (age ≤ 60 years old) were consecutively recruited
from the First People’s Hospital of Foshan (Foshan,
China) and the Affiliated Hospital of Guangdong Medical
University (Zhanjiang, China) from March 2011 to
February 2013. All the patients were newly diagnosed
and previously untreated. Coronary angiography was ini-
tially performed to clarify the origin of chest pain or elec-
trocardiographic abnormalities at rest or during exercise
test. The diagnosis of CAD was confirmed by coronary
angiography performed with the Judkins technique using
a quantitative coronary angiographic system. CAD was
defined as angiographic evidence of at least one segment
of a major epicardial coronary artery with more than 50 %
organic stenosis. Two cardiologists who were responsible
for the assessment of angiograms both underwent strict
training and complied with the same diagnostic criteria.
Subjects with a history of hematologic, neoplastic, renal,
liver, or thyroid diseases were excluded.
All subjects enrolled in this study were genetically unre-
lated ethnic Han Chinese. Each subject was interviewed to
collect information on demographic data and risk factors
related to CAD after obtaining the informed consent. The
study was approved by the Medical Ethics Committee of
the First People’s Hospital of Foshan and the Affiliated
Hospital of Guangdong Medical University.
Biochemical parameters analysis
The blood sample drawn from each subject was centri-
fuged at 2000 × g for 15 min immediately after collection
Table 1 The characteristics of early-onset CAD cases and
controls
Variable Controls (n = 297) Cases (n =224) P-valuea
Age (years) 50.49 ± 6.85 51.66 ± 6.47 0.048b
Sex (male) 171 (57.6 %) 177 (79.0 %) <0.001
Smoking 86 (29.0 %) 140 (62.5 %) <0.001
Drinking 47 (15.8 %) 71 (31.7 %) <0.001
Hypertension 82 (27.6 %) 142 (63.4 %) <0.001
Diabetes 45 (15.2 %) 115 (51.3 %) <0.001
Hyperlipidemia 123 (41.4 %) 169 (75.4 %) <0.001
Systolic BP (mm Hg) 129.44 ± 16.17 141.68 ± 18.88 <0.001
Diastolic BP (mm Hg) 72.96 ± 9.91 76.87 ± 10.80 <0.001
FPG (mmol/L) 5.85 ± 2.36 6.67 ± 1.58 <0.001
Triglycerides (mmol/L) 1.60 ± 0.96 2.19 ± 1.09 <0.001
Total cholesterol (mmol/L) 4.64 ± 1.19 4.79 ± 1.27 0.160
LDL cholesterol (mmol/L) 1.45 ± 0.89 1.18 ± 0.34 <0.001
HDL cholesterol (mmol/L) 2.63 ± 0.99 3.08 ± 0.94 <0.001
aTwo-sided chi-square test or independent-samples t-test
bP values under 0.05 were indicated in bold font
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terol (TC), triglyceride (TG), high density lipoprotein
cholesterol (HDL-C), and low density lipoprotein choles-
terol (LDL-C) were measured enzymatically using a chem-
istry analyzer (Olympus, Japan). Glucose was analyzed by
the glucose oxidase method with an Abbott V/P Analyzer
(Abbott Laboratories, USA).
DNA extraction
Genomic DNA was extracted from peripheral whole
blood by TIANamp blood DNA extraction kit (TianGen
Biotech, Beijing, China) according to the manufacturer’s
instructions. All DNA samples were dissolved in water
and stored at −20 °C until use.
Genotyping
SNPs genotyping were performed utilizing polymerase
chain reaction-ligase detection reaction (PCR-LDR)
method (Shanghai Biowing Applied Biotechnology
Company), as described in our previous study [28].
The sequence of primers and probes were listed in
Additional file 1: Table S1.
Statistical analysis
All the three SNPs were tested for confirmation with
Hardy-Weinberg expectations by a goodness-of-fit χ2
test among the control subjects. Quantitative variables
were expressed as mean ± standard deviation (SD), and
qualitative variables were expressed as percentages. The
differences of the demographic characteristics between
the cases and controls were estimated using the χ2 test
(for categorical variables) and Student’s t test (for con-
tinuous variables).
Multivariate association analyses with CAD risk, geno-
type frequencies were assessed by means of multivariate
methods based on logistic regression analysis, the odds
ratios (ORs) and 95 % confidence intervals (CIs) for the
effect of SNPs on CAD risk adjusted by age, sex, smok-
ing, drinking, hypertension, diabetes and hyperlipidemia.
Association analyses between SNPs and blood lipid pro-
files were performed by one-way analysis of variance
(ANOVA). The statistical analyses were performed using
the SPSS software (version 21). A P value of less than
0.05 was used as the criterion of statistical significance.
Results
Characteristics of the study population
The characteristics of CAD cases and control subjects
were listed in Table 1. In the lipid profiles comparison,
TG and LDL-C were significantly higher in CAD pa-
tients than that in controls (P < 0.001, P < 0.001, respect-
ively), whereas serum HDL-C levels were significantly
higher among controls (P < 0.001), and no statistically
significant difference between cases and controls wasobserved in TC levels (P = 0.160). Besides, the average
fasting plasma glucose (FPG) in CAD cases was signifi-
cantly higher than in controls (P < 0.001). CAD cases
had higher levels of systolic blood pressure, diastolic
blood pressure; the prevalence of smokers, alcohol con-
sumers, and individuals with hypertension, diabetes or
hyperlipidemia was significantly higher among the CAD
patients. In addition, the number of female subjects in
CAD cases was much lower than the male subjects. In
all, these data demonstrated that male gender, smoking,
alcohol intake, hypertension, hyperlipidemia and dia-
betes mellitus were the critical risk factors for premature
CAD development in Chinese population.
Multivariate associations of four SNPs with the risk of
premature CAD
Four SNPs (rs5167 and rs1132899 in APOC4, rs1801693
and rs7765781 in LPA) were genotyped in 224 CAD pa-
tients and 294 control subjects (≤60 years old). The pri-
mary information for rs5167, rs1132899, rs1801693 and
rs7765781 polymorphisms was listed in Table 2. Minor
allele frequency (MAF) of all three SNPs in our controls
was similar to MAF for Chinese in HapMap database
(Table 2). All the genotype frequency distributions of
the three SNPs in our control subjects followed Hardy-
Weinberg equilibrium proportions (all P values ≥ 0.10,
Table 2).
The allele and genotype distributions of the four SNPs
in the cases and the controls were shown in Table 3.
From the allelic association analysis, we found only
rs1132899 showed statistical significance, and C allele
was associated with a significantly increased risk of CAD
Table 2 Primary information for rs1132899, rs5167, rs6687605 and rs13306731 SNPs
Genotyped SNPs rs1132899 rs5167 rs1801693 rs7765781
Chr Pos (Genome Build 104.0) 45448036 45448465 160969629 161007496
Gene APOC4 Exon 2 APOC4 Exon 3 LPA Exon32 LPA Exon26
MAFa for Chinese(CHB) in HapMap 0.244 0.366 0.439 0.489
MAF in our controls (n = 650) 0.328 0.481 0.449 0.359
P Value for HWEb test in our controls 0.597 0.507 0.813 0.838
aMAF: minor allele frequency
bHWE: Hardy–Weinberg equilibrium
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addition, compared to TT genotype, the CC genotype
exhibited an increased risk of CAD as well (OR = 2.84,
95 % CI = 1.17–6.92, P = 0.022, Table 3). These data indi-
cated that APOC4 SNP rs1132899 was associated with
premature CAD risk (age ≤ 60 years old), and that individ-
uals carrying C allele might have significantly increasedTable 3 Multivariate associations of the SNPs in APOC4 and LPA
gene with the risk of premature CAD
Type Controls (n= 297) Cases (n= 224) OR (95 % CI)a P-valuea
No. (%) No. (%)
APOC4 rs1132899
T 195 (32.8) 132 (29.5) 1.00 -
C 399 (67.2) 316 (70.5) 1.50 (1.05–2.14) 0.027b
TT 30 (10.1) 15 (6.7) 1.00 -
CT 135 (45.5) 102 (45.5) 2.15 (0.89–5.20) 0.089
CC 132 (44.4) 107 (47.8) 2.84 (1.17–6.92) 0.022
APOC4 rs5167
T 286 (48.1) 217 (48.4) 1.00 -
G 308 (51.9) 231 (51.6) 0.75 (0.54–1.03) 0.078
TT 66 (22.2) 47 (21.0) 1.00 -
GT 154 (51.9) 123 (54.9) 1.35 (0.78–2.35) 0.289
GG 77 (25.9) 54 (24.1) 1.79 (0.94–3.43) 0.078
LPA rs1801693
T 327 (55.1) 249 (55.6) 1.00 -
C 267 (44.9) 199 (44.4) 0.94 (0.70–1.28) 0.707
TT 89 (30.0) 71 (31.7) 1.00 -
CT 149 (50.2) 107 (47.8) 1.00 (0.61–1.65) 0.997
CC 59 (19.8) 46 (20.5) 1.14 (0.62–2.10) 0.681
LPA rs7765781
C 213 (35.9) 159 (35.5) 1.00 -
G 381 (64.1) 289 (64.5) 1.04 (0.76–1.43) 0.807
CC 39 (13.1) 28 (12.5) 1.00 -
CG 135 (45.5) 103 (46.0) 1.16 (0.59–2.25) 0.674
GG 123 (41.4) 93 (41.5) 1.13 (0.58–2.22) 0.724
aAdjusted for age, sex, smoking, drinking, hypertension, diabetes
and hyperlipidemia
bP values under 0.05 were indicated in bold fontCAD susceptibility. However, we did not find any associ-
ation between rs5167, rs1801693 and rs7765781 and the
risk of CAD (Table 3).
Stratification analyses of APOC4 rs1132899 polymorphism
and risk of CAD
We further evaluated the alleles or genotypes of APOC4
rs1132899 and CAD susceptibility after stratifying the
subjects by sex, status of smoking or drinking. Stratifica-
tion analyses by sex revealed that the increased risk of
CAD was more evident among male subjects carrying C
allele (OR = 1.65, 95 % CI = 1.06–2.58, P = 0.028, Table 4)
or the CC genotype (OR = 3.33, 95 % CI =1.14–9.69,
P = 0.027, Table 4). In addition, only the CC genotype
of rs1132899 polymorphism exhibited an association
with enhanced risk of CAD in smokers (OR = 3.59,
95 % CI =1.08–12.0, P = 0.037, Table 4), but not in
non-smokers. No more evident association between
APOC4 rs1132899 polymorphism and risk of CAD
was observed among subgroups by status of drinking
(data not shown).
Multivariate associations of the APOC4 SNPs with the lipid
profile
In order to probe into the potential explanation to the
enhanced effects of APOC4 rs1132899 polymorphism on
early-onset CAD risk (≤60 years old), we further analyzed
the association between APOC4 rs1132899 polymorphismTable 4 Multivariate associations of the rs1132899 in APOC4
gene with the risk of CAD by further stratification for sex and
smoking status
Male Smokers
Genotype OR (95 % CI)a p-valuea OR (95 % CI)b P-valueb
T 1.00 - 1.00 -
C 1.65 (1.06–2.58) 0.028a 1.58 (0.93–2.70) 0.094
TT 1.00 - 1.00 -
CT 2.29 (0.80–6.57) 0.123 3.07 (0.95–9.96) 0.061
CC 3.33 (1.14–9.69) 0.027c 3.59 (1.08–12.0) 0.037
aAdjusted for age, smoking, drinking, hypertension, diabetes
and hyperlipidemia
bAdjusted for age, sex, drinking, hypertension, diabetes and hyperlipidemia
cP values under 0.05 were indicated in bold font
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the above lipids profile exhibited significant association
with APOC4 rs1132899 polymorphism (data not shown).
Nonetheless, CC genotype of rs1132899 conferred about
0.09 mmol/L increase in triglyceride (TG) levels compared
to CT/TT genotype (1.95 mmol/L vs 1.86 mmol/L) in
male subjects compared to CT/TT genotype, though the
difference was non-significant (Table 5). Thus, these re-
sults indicated that, in addition to influence the lipid pro-
file, there might be other mechanisms contributing the
increased risk of APOC4 rs1132899 polymorphism in pre-
mature CAD, which still require further analysis in a lar-
ger sample size.
Discussion
The fundamental pathogenesis of CAD is the dysfunc-
tion of lipid metabolism, and thus the disorder of plasma
lipid profile, which caused by both individual’s genetic
makeup and various environmental factors. Previous
studies have demonstrated the effects of APOC4 and
LPA in abnormal blood lipids including hypercholester-
olemia or hypertriglyceridemia, indicating the potential
role of APOC4 and LPA in the CAD development.
Nonetheless, the association between SNPs in APOC4
and LPA gene and CAD risk still required to be fully elu-
cidated. The potential risk of CAD in older subjects is
more likely due to the aging effects as weak immune sys-
tem and relative high level exposure to environmental
risk factors, rather than direct genetic effects. Thus, in
this study, we performed a genetic association analysis
on the four SNPs (rs1132899 and rs5167 in APOC4,
rs1801693 and rs7765781 in LPA) among early-onset
CAD subjects (≤60 years old). Our data revealed that the
APOC4 rs1132899 polymorphism was associated with
increased risk of both premature CAD, and the associ-
ation was more remarkable among male subjects. Taken
together, our study suggested that APOC4 polymor-
phisms might play an important role in the early-onset
CAD pathogenesis.
The APOE/C1/C4/C2 gene cluster has been estab-
lished to be a critical region for several human diseases,
including CAD, and thus the polymorphisms of the
locus have been considered to be closely associated withTable 5 ANOVA analysis of the association between rs1132899 in AP
stratification for sex
Variable Male
CC CT + TT
Triglycerides (mmol/L) 1.95 ± 1.13 1.86 ± 1.08
Total cholesterol (mmol/L) 4.65 ± 1.20 4.67 ± 1.23
LDL cholesterol (mmol/L) 2.83 ± 1.02 2.81 ± 0.87
HDL cholesterol (mmol/L) 1.34 ± 1.17 1.22 ± 0.34
aTwo-sided chi-square test or independent-samples t-testthe risk of CAD. However, the effects of APOC4
rs1132899 and rs5167 polymorphisms on CAD risk are
still unknown. Kamboh et al. has reported that the
rs1132899 and rs5167 polymorphisms were significantly
associated with triglyceride levels in women; moreover,
APOC4 rs5167 polymorphism exerted a modest effect
on HDL-C levels. Hypertriglyceridemia and hypercholes-
terolemia are crucial risk factors for atherosclerosis,
CAD and other arterial cardiovascular diseases, which
indicated the important role of the two APOC4 poly-
morphisms during CAD development. Our data found
that rs1132899 endowed C allele carriers with significant
increased CAD risk, which is in consistent with the re-
sults from the above association analysis between the
two polymorphisms and plasma lipids levels.
Our stratified analyses revealed that the increased risk
of APOC4 rs1132899 polymorphism in CAD was more
evident among male subjects, whereas no significant as-
sociation was observed from the female group (Table 4).
The potential explanation to the gender variance is as
follow: 1. Previous studies have unraveled that the most
common risk factor in young men was cigarette smok-
ing, while the major risk factor was hypercholesterol-
aemia in young women [29]. Our data showed that the
rs1132899 polymorphism only exhibited an association
with enhanced risk of CAD in smokers, but not in non-
smokers, which was consistent with the association in
male subjects (Table 5); 2. The stratified analyses showed
that the CC genotype of rs1132899 modestly increased
the triglyceride (TG) levels compared in male subjects,
whereas female subjects carrying CC genotype exhibited
mildly decreased TG levels; 3. Sex hormones play an im-
portant role in coronary artery disease, a proper ratio of
estrogen:testosterone is essential during CAD develop-
ment s [30], which might account for the sex variance of
rs1132899 polymorphism for the risk of CAD.
Several limitations in this case–control study still need
to be addressed. First, the case subjects and controls en-
rolled from hospitals may not represent the general
population. However, the genotype distribution of the
controls was in Hardy-Weinberg equilibrium. Second,
the moderate sample size limited the statistical power of
our study, especially for the case subjects. Finally, furtherOC4 gene and the LDL-C, HDL-C, TC and TG levels by further
Female
P-valuea CC CT + TT P-valuea
0.457a 1.68 ± 084 1.81 ± 1.03 0.367
0.870 4.82 ± 1.07 4.74 ± 1.41 0.668
0.882 2.83 ± 1.02 2.83 ± 1.16 0.996
0.191 1.42 ± 0.35 1.45 ± 0.48 0.609
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the significance of the association between the rs1132899
polymorphism and the risk of early-onset CAD. However,
our results provided valuable insights and interesting in-
formation and might serve to guide future studies in this
area.
Conclusions
In aggregate, our study firstly uncovered that the C allele
of APOC4 rs1132899 was associated with an increased
risk of early-onset CAD in a Chinese population, and the
association is more evident among male subjects, which
potentially due to the modestly elevated TG levels. Further
studies with larger sample size and in diverse ethnic popu-
lations are required to confirm the general validity of our
findings.
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